Next-Generation Obesity Target Spotlight: Activin E for Fat Loss with Muscle Preservation

As lifestyle interventions struggle to overcome metabolic rebound and GLP-1 therapies face limitations such as lean mass loss and suboptimal body composition control, the Activin E-ALK7 signaling pathway is emerging as a highly promising breakthrough target in obesity and metabolic drug development for 2026. With its unique potential to drive targeted fat reduction while preserving muscle mass, together with a well-defined mechanism in metabolic regulation, this pathway provides strong scientific rationale for next-generation therapeutic development and accelerates global pharmaceutical interest in the field.

Activin E: A Central Regulator of Liver-Adipose Metabolic Crosstalk

INHBE is a key metabolic regulatory gene within the TGF-β superfamily and is predominantly expressed in the liver. The encoded subunits dimerize to form Activin E, a circulating hepatokine that plays an important role in systemic energy homeostasis. After secretion into the bloodstream, Activin E binds to ALK7 receptors on adipocytes and activates downstream Smad2/3 signaling. Its primary function is to suppress lipolysis and promote fat storage, thereby fine-tuning whole-body metabolic balance.

- Under normal physiological conditions, elevated serum free fatty acids and hepatic triglyceride levels stimulate hepatocytes to secrete more Activin E. Through this liver-to-adipose signaling axis, Activin E restrains adipocyte lipolysis via the ALK7-Smad pathway, limiting fatty acid flux back to the liver and helping protect against excessive hepatic lipid accumulation and nonalcoholic fatty liver disease (NAFLD).

- In obesity, however, chronic overactivation of the Activin E pathway may become maladaptive. Excessive suppression of lipolysis effectively "locks" fat within adipose tissue, contributing to persistent fat accumulation, impaired weight loss, worsening obesity, and insulin resistance. This may ultimately drive a vicious metabolic cycle of obesity, elevated Activin E signaling, suppressed fat breakdown, and further weight gain.

https://doi.org/10.1038/s12276-025-01403-6

Activin E suppresses lipolysis in adipocytes via the ALK7-Smad pathway

A 2025 study published in Experimental & Molecular Medicine demonstrated that Activin E directly suppresses adipocyte lipolysis through the ALK7-Smad signaling pathway. Loss of INHBE led to excessive adipose lipolysis, a surge of free fatty acids into the liver, and ultimately severe hepatic steatosis. In contrast, INHBE overexpression suppressed lipolysis and alleviated liver fat accumulation, further validating the critical role of this pathway in metabolic regulation. Based on this mechanism, therapeutic strategies such as INHBE silencing, blocking Activin E-ALK7 interaction, or neutralizing Activin E protein may help disrupt the pathogenic cycle driving obesity and metabolic dysfunction.

INHBE-Activin E-ALK7: A Precision Fat-Loss Pathway Delivering Strong Clinical Validation

In Q1 2026, leading companies including Arrowhead Pharmaceuticals and Wave Life Sciences reported encouraging clinical data from RNAi therapies targeting the INHBE-Activin E-ALK7 pathway, further validating its translational potential in metabolic disease.

Arrowhead's ARO-INHBE achieved an average 85% reduction in circulating Activin E levels following a single 400 mg dose. At Week 16, patients showed a 9.9% reduction in visceral fat, a 38.6% decrease in liver fat, and a 3.6% increase in lean mass. After two doses over 24 weeks, visceral fat reduction further improved to 15.6%. In combination with Tirzepatide, patients with obesity and type 2 diabetes achieved 9.4% body weight loss, along with 23.2% and 76.7% reductions in visceral and liver fat, respectively. Its companion program, ARO-ALK7, demonstrated the first efficient in vivo gene silencing of adipocytes in humans, achieving an 88% reduction in ALK7 mRNA at Week 8 and a 14.1% decrease in visceral fat after a single dose.

Wave's WVE-007 also delivered promising Phase I results. Six months after a single administration, visceral fat was reduced by 14.3% while lean mass increased by 2.4%. By inhibiting the Activin E-ALK7-Smad2/3 signaling axis, the therapy promotes targeted fat breakdown and reduces fat storage without suppressing appetite or compromising muscle mass. Its long-acting, low-frequency dosing profile may also help address the body composition limitations commonly associated with GLP-1 therapies.

Recent pipeline progress and therapeutic advances

Beyond RNAi therapies, antibody drugs and pathway inhibitors are also progressing steadily. Although no Activin E-targeted anti-obesity therapy has entered clinical trials yet, the pathway's differentiated "selective fat-loss" mechanism-along with related deals involving iBio, Inc. and AstralBio-is expected to attract increasing pharma interest.

On March 9, 2026, iBio, Inc. released preclinical non-human primate data for its Activin E antibody candidate IBIO-610. After two doses over eight weeks, visceral fat decreased by 6.7% and total fat mass by 5.2%, with only minimal lean mass gain, consistent with prior rodent and related human studies. IBIO-610 showed a 33.2-day half-life in non-human primates and a projected ~100-day half-life in humans, potentially supporting twice-yearly dosing. Combined with Semaglutide, total fat reduction reached 72%. In addition, Laekna Therapeutics is developing LAE123, a dual Activin RIIA/Activin RIIB inhibitor that suppresses Activin E signaling and is currently in IND-enabling studies.

ACROBiosystems Supports Obesity Drug Development
Activin E-ALK7 Product Portfolio

From Weight Loss to Healthy Body Recomposition: A New Era in Metabolic Therapy

The Activin E-ALK7 pathway offers several key advantages, including fat reduction with muscle preservation, targeted reduction of liver fat, and long-acting safety benefits. By directly addressing key limitations of conventional weight-loss approaches and GLP-1 therapies, it has emerged as a potentially disruptive target in metabolic disease. As multiple therapeutic modalities-including RNAi therapies, monoclonal antibodies, and receptor inhibitors-continue to advance rapidly, the expanding pipeline around this pathway is expected to drive broader applications in target validation, drug screening, functional characterization, and quality control. Together, these efforts may accelerate the development of next-generation differentiated anti-obesity therapies and benefit patients worldwide with obesity and metabolic disorders.

Related Articles

References

1. Park S Y, Cho Y, Son S M, et al. Activin E is a new guardian protecting against hepatic steatosis via inhibiting lipolysis in white adipose tissue[J]. Experimental & molecular medicine, 2025, 57(2): 466-477. https://doi.org/10.1038/s12276-025-01403-6

2. Griffin J D, Buxton J M, Culver J A, et al. Hepatic Activin E mediates liver-adipose inter-organ communication, suppressing adipose lipolysis in response to elevated serum fatty acids[J]. Molecular Metabolism, 2023, 78: 101830. https://doi.org/10.1016/j.molmet.2023.101830